CLL Coverage from Every Angle

William G. Wierda, MD, PhD, on CLL/SLL: 3-Year Follow-up Data on Ibrutinib Plus Venetoclax

Posted: Monday, June 27, 2022

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the CAPTIVATE study, which showed that fixed-duration first-line treatment with ibrutinib plus venetoclax continues to provide deep, durable responses and clinically meaningful progression-free survival in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high-risk disease features. This regimen represents an all-oral, once-daily, chemotherapy-free treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.